DR RICHARD BOGLE PHD FRCP FESC FACC DHMSA CONSULTANT CARDIOLOGIST
  • Home
  • Blog
  • NHS Practice
    • NHS Practice
    • St Helier Hospital
    • Epsom Cardiac Day Unit
    • St George's Hospital Radial Lounge
    • Echocardiography
  • Biography
    • Qualifications
    • About me >
      • Curriculum vitae
    • Appraisal and Revalidation
    • BCIS Angioplasty Audit
    • Publications
    • Recent abstracts
    • Research
    • Charitable activity
  • The Heart
    • Cardiac Investigations >
      • AliveCor ECG monitor
      • Guide to investigations for suspected angina
      • CT calcium scoring
      • Electrocardiogram (ECG)
      • Exercise treadmill test
      • Echocardiogram
      • Valve disease
      • Coronary Angiography
      • Pressure Wire Studies
      • Intra-vascular Ultrasound
    • Arrhythmias >
      • Atrial fibrillation >
        • Stroke Risk in AF
        • New Oral Anticoagulants
        • Presentations on AF
      • Atrial flutter
      • Pre-excitation syndromes
      • Ventricular ectopic beats
      • Ventricular arrhythmias
      • Pacemaker
      • DC Cardioversion
    • Cardiomyopathy
    • Coronary heart disease >
      • Cardiac syndrome X
      • Coronary Angioplasty
      • Coronary bypass surgery
    • Dizziness and blackouts
    • Fitness to fly
    • Fitness to drive
    • Heart Failure
    • Hypertension >
      • Patients guide to blood pressure medication
      • Home blood pressure monitors
      • Hypertension diet
      • Laragh's method
      • Renal sympathetic ablation for hypertension
      • Conn's Syndrome
    • Heart Screening >
      • Sports Cardiology
      • Cardiovascular Disease Risk
    • Medications >
      • Glyceryl trinitrate
    • Patient information leaflets
  • News and Links
  • Miscellany
    • History of Medicine
    • History of Coronary Angiography and Angioplasty
    • Stamps in Cardiology
    • A History of Medicine in 100 Objects
    • BSE Acceditation Course Introduction
    • BSE Acceditation Course Physics
    • BSE Acceditation Course Anatomy and Function
    • BSE Acceditation Course Mitral
    • BSE Acceditation Course Aortic
    • BSE Acceditation Course Congenital
    • BSE Acceditation Course Pericardium
    • RACPC Form
    • Cardiology Teaching St Helier Hospital

Is it time to reconsider Rivaroxaban?

28/2/2016

2 Comments

 
Direct acting oral anticoagulants (DOAC) have revolutionised the management of atrial fibrillation (AF).  There are four medicines licenced to reduce the risk of stroke and thromboembolism in patients with non-valvular AF – Apixaban, Dabigatran, Edoxaban and Rivaroxaban.

Each DOAC has been compared to Warfarin in large randomised clinical trials and all have shown either non-inferiority or in some cases slight superiority to Warfarin. It is difficult to compare the drugs head-to-head because the trials all had slightly different design however recently there has been some uncertainty about the Rivaroxaban ROCKET-AF trial. Rivaroxaban has become one of the most popular DOACs because of its once daily dose regimen and is very well-tolerated. To date it has been my DOAC of choice.

The ROCKET-AF trial was criticised after publication for potentially being biased in favour of Rivaroxaban. This was because the time in the therapeutic range for the Warfarin patients was just 55%. In other words, the INR of patients on Warfarin was between 2 and 3 just over half the time.  The optimum time in the therapeutic range for a patient on warfarin should be >70%.

More recently the trial has come under fire because the INR monitoring was performed using a point-of-care device that has been subsequently recalled by the FDA. The device produced inaccurately low INR results in some patients. This had the potential to produce falsely low INR readings. This meant that the dose of Warfarin prescribed would have been increased thus exposing patients to potentially higher bleeding tendency.

The faulty INR machine used in the trial led to potential overdosing of warfarin which could have led to higher bleeding in the warfarin group. However, in the trial the annual risk of major bleeding was 3.6% with Rivaroxaban versus 3.4% with Warfarin. If the patients on Warfarin had a higher bleeding tendency because nearly 40% were being over-treated this could have increased the major bleeding rate in the Warfarin group and difference in major bleeding caused by Rivaroxaban

The trial authors have now responded to this by publishing a Research letter in the New England Journal of Medicine. They reporting that 37% of patients treated with Warfarin had a condition that could have been affected by the faulty INR device. They performed an analysis of these patients and reported that the main results of the trial were unaffected.  
Sceptics have responded in an article in the British Medical Journal calling for release of the patient-level data as they don’t trust the investigators analysis. So far the company have not indicated that they will release the data.
Should we continue to prescribe Rivaroxaban for new patients and should patients currently on the drug be confident to continue taking it?

In the post-marketing Xantus study with Rivaroxaban the annual rate of major bleeding was 2.1%, stroke 0.7%, and death 1.9% which were either equivalent to or less than those reported in ROCKET-AF. So in real life clinical practice the drug appears to perform in a manner similar to that achieved in the ROCKET-AF trial. Although that is not surprising since it was the Warfarin comparator group where the problem lies and therefore interpreting difference between Warfarin and Rivaroxaban.

Up to this point the main reasons to choose Rivaroxaban are the simple once-daily dosing and good tolerability. Recently Edoxaban has been launched in the UK and this is also once daily. In the clinical trial of Edoxaban versus Warfarin time in the therapeutic range was 68.4%, which is good and a different point of care INR monitoring machine was used. The average CHADS2 score in the trial was 2.8 and Edoxaban was non-inferior to Warfarin for stroke prevention with a trend towards a lower annualised risk of major bleeding of 2.75% versus 3.43% with Warfarin. Certainly Edoxaban looks an attractive candidate to become my DOAC of choice going forward. 
2 Comments
A person via Twitter
28/2/2016 06:41:41 am

Why not apixaban? They tout good tolerability and efficacy.

Reply
Richard Bogle
28/2/2016 09:23:16 am

No reason not to use Apixaban, but Edoxaban is a once daily medicine so its easier to remember to take it.

Reply

Your comment will be posted after it is approved.


Leave a Reply.

    RSS Feed

    Picture

    Dr Richard Bogle

    The opinions expressed in this blog are strictly those of the author and should not be construed as the opinion or policy of my employers nor recommendations for your care or anyone else's. Always seek professional guidance instead.

    Archives

    August 2023
    November 2019
    March 2016
    February 2016
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    November 2013
    October 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013

    Categories

    All
    Ablation
    Acute Coronary Syndromes
    Acute Coronary Syndromes
    Adherence
    Angioplasty
    Anticoagulants
    Arrhythmia
    Association
    Atherosclerosis
    Atrial Fibrillation
    Auenbrugger
    Bergamot
    Brugada
    Calcium Channel Blockers
    Cancer
    Cardiovascular Risk
    Chest Pain
    Cholesterol
    Cleveland Street
    Clinical Examination
    Colchicine
    Compliance
    Concordance
    Congenital Heart Disease
    Coronary Artery Disease
    Coronary Artery Disease
    C-reactive Protein
    Decision Aids
    Diet
    Ectopics
    Eggs
    Ezetimibe
    Frailty
    Frank's Sign
    Guidelines
    Hawthorne Effect
    Heart Failure
    History Of Medicine
    Hypertension
    ICD
    Internet
    Interventional Cardiology
    Joseph Rogers
    Lipids
    Malaria
    Marathon
    Medicines
    Nice Guidelines
    Nitrovasodilators
    NOAC
    Nudge
    Nutrition
    OCT
    Palpitations
    Pharmacy
    Pressure Wire
    Proteus
    Salt
    Smoking
    Spironolactone
    Statins
    Statistics
    Stent
    Stress
    Stroke
    Syndrome X
    Takotsubo
    Valve-disease
    Vein Grafts
    Ventricular Ectopics
    VF/VT
    Warfarin
    Weekend Working
    Workhouse

    View my profile on LinkedIn
Return to home page

Privacy Statement
Disclaimer
© Dr Richard Bogle 2020
patient feedback
Photo used under Creative Commons from peddhapati
  • Home
  • Blog
  • NHS Practice
    • NHS Practice
    • St Helier Hospital
    • Epsom Cardiac Day Unit
    • St George's Hospital Radial Lounge
    • Echocardiography
  • Biography
    • Qualifications
    • About me >
      • Curriculum vitae
    • Appraisal and Revalidation
    • BCIS Angioplasty Audit
    • Publications
    • Recent abstracts
    • Research
    • Charitable activity
  • The Heart
    • Cardiac Investigations >
      • AliveCor ECG monitor
      • Guide to investigations for suspected angina
      • CT calcium scoring
      • Electrocardiogram (ECG)
      • Exercise treadmill test
      • Echocardiogram
      • Valve disease
      • Coronary Angiography
      • Pressure Wire Studies
      • Intra-vascular Ultrasound
    • Arrhythmias >
      • Atrial fibrillation >
        • Stroke Risk in AF
        • New Oral Anticoagulants
        • Presentations on AF
      • Atrial flutter
      • Pre-excitation syndromes
      • Ventricular ectopic beats
      • Ventricular arrhythmias
      • Pacemaker
      • DC Cardioversion
    • Cardiomyopathy
    • Coronary heart disease >
      • Cardiac syndrome X
      • Coronary Angioplasty
      • Coronary bypass surgery
    • Dizziness and blackouts
    • Fitness to fly
    • Fitness to drive
    • Heart Failure
    • Hypertension >
      • Patients guide to blood pressure medication
      • Home blood pressure monitors
      • Hypertension diet
      • Laragh's method
      • Renal sympathetic ablation for hypertension
      • Conn's Syndrome
    • Heart Screening >
      • Sports Cardiology
      • Cardiovascular Disease Risk
    • Medications >
      • Glyceryl trinitrate
    • Patient information leaflets
  • News and Links
  • Miscellany
    • History of Medicine
    • History of Coronary Angiography and Angioplasty
    • Stamps in Cardiology
    • A History of Medicine in 100 Objects
    • BSE Acceditation Course Introduction
    • BSE Acceditation Course Physics
    • BSE Acceditation Course Anatomy and Function
    • BSE Acceditation Course Mitral
    • BSE Acceditation Course Aortic
    • BSE Acceditation Course Congenital
    • BSE Acceditation Course Pericardium
    • RACPC Form
    • Cardiology Teaching St Helier Hospital